Building and Scaling the Tools and Technologies that Underpin Lifesciences

About this episode

A conversation with Martin Madaus on value creation in life sciences and the challenges faced by tool companies.

In this episode of Boba & Biotech, I go for a tasty brown sugar milk tea with Martin Madaus, former CEO of one of the biggest technology providers in our field, Millipore, for a wide-ranging conversation on what actually creates value in life sciences. Martin traces his unconventional path from veterinary medicine to global leadership roles across pharma, diagnostics, and life science tools, and shares hard-earned perspective on platform businesses versus therapeutics, why tool companies often struggle with adoption, and when M&A truly makes sense. He pushes back on the idea that therapeutics are intellectually “superior” to tools and highlights underappreciated technologies like MRD testing and spatial proteomics. Martin also makes a forceful case for moving beyond animal testing in favor of organ-on-chip models. The episode closes with a look at where real clinical impact may come next - from cell therapies to emerging innovation out of China. Martin Madaus is a seasoned public-company CEO, who has led and advised diagnostics and life science tools companies for decades, including serving as Chairman and CEO of Ortho Clinical Diagnostics and as President, Chairman, and CEO…

People in this episode

Host: Armon Sharei

Guest: Martin Madaus

Topics covered

• life sciences
• value creation
• pharmaceuticals
• diagnostics
• life science tools
• M&A
• animal testing
• organ-on-chip models
• cell therapies
• innovation

Keywords

• brown sugar milk tea
• platform businesses
• therapeutics
• MRD testing
• spatial proteomics
• clinical impact
• China

Mentioned in this episode

Products: Millipore, Ortho Clinical Diagnostics, Roche Diagnostics

Books & works: Ph.D.

Places: China

More episodes of Boba & Biotech

• Learning Biotech, Surviving Near-Death, and Seeing What Others Don’t · April 23, 2026 · 1h 11m
• Inside the Biotech Incubator: What Early Companies Get Right (and Wrong) · April 9, 2026 · 44 min
• What should become a company? Lessons from an academic at the center of biotech translation · March 26, 2026 · 39 min
• From Lab to Company: Engineering the Next Generation of Biotech Founders · March 13, 2026 · 53 min
• Money Meets Molecules: What Biotech Investors Actually Care About · February 26, 2026 · 43 min
• Introducing Boba & Biotech: The Only Thing We Sugarcoat is the Boba · January 29, 2026 · 39 min